20240225-太平洋-生物医药Ⅱ行业周报_溶瘤病毒疗法初显峥嵘_乐普生物布局领先_18页_1mb

• Oncolytic Virus Therapy Overview: The report highlights the growing interest in oncolytic virus therapy, which uses modified viruses to target and destroy cancer cells, with potential in specific treatments. C-G Oncology's CG0070, a key product, demonstrated high efficacy in treating non-muscle-invasive bladder cancer (NMIBC), achieving complete response rates of 75.7% in clinical trials, with good safety profiles, making it a promising option.

• Market Growth and Potential: The global oncolytic virus market is projected to expand significantly, reaching $24.79 billion by 2030 with a CAGR of over 29%. China's market is expected to grow from $0.02 billion in 2021 to $33.83 billion by 2030, driven by partnerships like CG0070's collaboration with ImmVirX for combined trials with immune-oncology drugs, potentially enhancing efficacy.

• Investment Recommendations: Focus on "single product innovation," such as CNS drugs (e.g., Elelytin Biosciences), and "out-of-country opportunities," including companies like Leptin Biosciences and medical device firms for revenue growth. Key companies to monitor include Leptin Biosciences for its oncolytic virus developments and CROs like Biosontce Pharmaceutical.

• Market Performance: This week, the pharmaceutical sector saw mixed results; the biological sub-sector rose 209% overall, outperforming index funds like the CSI 300 despite sector-specific declines in medical device stocks. Healthcare ETFs gained due to rising valuations.

Key recommendations include pay attention to oncologic innovations and strategic partnerships for future growth.